LakeShore Biopharma Co., Ltd
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- LakeShore Biopharma Co., Ltd (OTCPK:LSBCF), formerly YS Biopharma Co., Ltd., is a Cayman Islands-incorporated biopharmaceutical company founded in 1994 and headquartered in Beijing, China, that discovers, develops, manufactures, and commercializes vaccines and therapeutic biologics targeting infectious diseases including rabies, hepatitis B, influenza, shingles, and coronavirus, as well as immuno-oncology therapeutics for cancer. The company's commercialized product is the YSJA freeze-dried human rabies vaccine (Vero cells), with cumulative sales exceeding 100 million units since launch; its proprietary PIKA immunomodulating technology platform, which activates TLR3, RIG-I, and MDA5 immune signaling pathways, underpins a pipeline including the PIKA rabies vaccine in phase I/III and preclinical trials, PIKA recombinant COVID-19 vaccine, PIKA YS-HBV-001 hepatitis B vaccine and PIKA YS-HBV-002 therapeutic vaccine for chronic HBV both in phase I and preclinical stages respectively, PIKA YS-ON-001 immuno-oncology candidate in phase I for pancreatic and hepatocellular cancers, PIKA influenza vaccine and shingles vaccine candidates in preclinical development, and additional discovery-stage rabies and other therapeutic targets. LakeShore Biopharma operates primarily in China with additional presence in Singapore, the United States, the Philippines, and the United Arab Emirates, serving markets focused on preventive vaccines and innovative treatments for high unmet medical needs in infectious diseases and oncology; the company employs approximately 573 people and generates revenue from the development, production, marketing, and sale of biopharmaceutical products. In May 2024, the company changed its name from YS Biopharma Co., Ltd. to LakeShore Biopharma Co., Ltd.; most recently, on November 4, 2025, it entered into a definitive merger agreement with Oceanpine Skyline Inc. and its wholly-owned subsidiary Oceanpine Merger Sub Inc. for a going-private transaction valuing the equity at approximately US$37 million, or US$0.90 per ordinary share representing a 15.4% premium to the August 15, 2025 closing price, funded by cash from Oceanpine Capital Inc. and equity rollover by existing shareholders including Oceanpine Investment Fund II LP, Oceanpine Capital Inc., and Crystal Peak Investment Inc. who collectively beneficially own over 50% of shares and have committed to vote in favor, with the merger expected to close in early 2026 subject to customary conditions.
LSBCF Investors Have Opportunity to Join LakeShore Biopharma Co., Ltd Fraud Investigation with the Schall Law Firm
LSB Industries, Inc. Schedules 2025 Third Quarter Results Release for Wednesday, October 29th and Conference Call for Thursday, October 30th
LakeShore Biopharma Announces Transition to OTC Market Following Nasdaq Delisting
LakeShore Biopharma Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee
LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company and Formation of Special Committee
LSB Industries, Inc. to Participate in Upcoming Investor Conferences
LakeShore Biopharma Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company
LakeShore Biopharma Announces Fiscal Year 2025 Financial Results
LSB Industries, Inc. Reports Operating Results for the 2025 Second Quarter
LSB Industries, Inc. Schedules 2025 Second Quarter Results Release for Tuesday, July 29th and Conference Call for Wednesday, July 30th
LakeShore Biopharma Announces US$15 Million Private Placement Financing
LSB Industries, Inc. to Participate in UBS Energy Transition and Decarbonization Conference on Wednesday, May 14th
LSB Industries, Inc. Reports Operating Results for the 2025 First Quarter
LakeShore Biopharma Announces the Official Launch of a Novel Packaging Solution for YSJA™ Rabies Vaccine (Vero Cell)
LSB Industries, Inc. Schedules 2025 First Quarter Results Release for Tuesday, April 29th and Conference Call for Wednesday, April 30th
LSB Industries, Inc. Appoints Riccardo Bertocco as an Independent Member of the Board of Directors
LSB Industries, Inc. Reports Operating Results for the 2024 Fourth Quarter and Full Year and Provides Product Sales Volume Outlook for 2025
LSB Industries, Inc. Schedules 2024 Fourth Quarter and Full Year Financial Results Release for Wednesday, February 26th and Conference Call for Thursday, February 27th
LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance
LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China